Journal of Clinical Endocrinology & Metabolism, Vol 72, 1136-1141, Copyright © 1991 by Endocrine Society

ARTICLES

The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine

AJ van der Lely, J Brownell and SW Lamberts
Department of Medicine, Erasmus University, Rotterdam, The Netherlands.

We studied the effect of CV 205-502 in 12 patients with macroprolactinomas and 8 patients with PRL-secreting tumors, who were selected because of previous repeatedly shown intolerance to bromocriptine in even small doses. We also investigated serum insulin- like growth factor-I (IGF-I) levels before and during CV 205-502 therapy. In 12 macroprolactinoma patients followed for 1 yr, 0.075- 0.450 mg CV 205-502 lowered PRL levels by 91.2 +/- 5.4%. Only 3 of the patients had transient side-effects of nausea, dizziness, or fatigue. In eight patients with PRL-secreting tumors who were bromocriptine intolerant, CV 205-502 (0.075-0.300 mg daily) lowered PRL levels by 80.2 +/- 6.3%. Four of these patients showed transient side-effects (nausea, fatigue, and/or tachycardia). None of the patients discontinued therapy. There was a close correlation between pretreatment circulating PRL levels and tumor size, expressed in cubic millimeters. The decrease in pituitary tumor size after 52 weeks of CV 205-502 therapy (-74 +/- 6%) was also correlated with the decrease in PRL levels (P less than 0.01). In four patients with hypopituitarism, lowered IGF-I levels did not change during CV 205-502 therapy. However, in seven previously untreated patients with macroprolactinoma and normal CV 205-502 is a potent dopaminergic drug, which effectively controls PRL secretion and induces tumor shrinkage. At the doses used in our study, it causes only mild and transient side-effects in a minority of patients and can also be used to treat hyperprolactinemic patients who have shown intolerance to bromocriptine therapy.

This article has been cited by other articles:

				J Kreutzer, R Buslei, H Wallaschofski, B Hofmann, C Nimsky, R Fahlbusch, and M Buchfelder Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients Eur. J. Endocrinol., January 1, 2008; 158(1): 11 - 18. [Abstract] [Full Text] [PDF]

				M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao Advances in the Treatment of Prolactinomas Endocr. Rev., August 1, 2006; 27(5): 485 - 534. [Abstract] [Full Text] [PDF]

				A. Barlier and P. Jaquet Quinagolide - a valuable treatment option for hyperprolactinaemia Eur. J. Endocrinol., February 1, 2006; 154(2): 187 - 195. [Abstract] [Full Text] [PDF]

				New drugs for hyperprolactinaemia DTB, September 1, 1995; 33(9): 65 - 67. [Abstract] [Full Text] [PDF]